Trial Profile

Efficacy of a Meningococcal B Vaccine Against Neisseria Gonorrhoeae Infections Among Men Who Have Sex With Men: a Randomised-controlled Clinical Trial

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Sep 2026 Primary endpoint has not been met. (Comparison between incidence of NG between two groups), according to results published in the International Journal of Infectious Diseases.
01 Sep 2026 Results assessing efficacy of the four-component meningococcal group B (4CMenB) vaccine against gonorrhea among MSM, published in the International Journal of Infectious Diseases.
19 Mar 2026 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com